Your browser doesn't support javascript.
loading
Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma.
Jia, Qingzhu; Qin, Diyuan; He, Feng; Xie, Qichao; Ying, Zhitao; Zhang, Yajing; Song, Yuqin; Cheng, Jia-Nan; Zuo, Xuejiao; Xu, Luxiang; Fang, Hongliang; Hu, Chunyan; Peng, Lina; Jin, Tao; Shi, Zixiao; Alexander, Peter B; Wang, Yongsheng; Liu, Yarong; Han, Weidong; Zhu, Jun; Wang, Pin; Li, Qi-Jing; Zhu, Bo.
Afiliação
  • Jia Q; Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.
  • Qin D; Chongqing Key Laboratory of Immunotherapy, Chongqing 400037, China.
  • He F; Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu 610041, China.
  • Xie Q; Department of Immunology, Duke University Medical Center, Durham, NC, USA.
  • Ying Z; Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.
  • Zhang Y; R&D Department, HRAIN Biotechnology Co. Ltd., Shanghai, China.
  • Song Y; Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.
  • Cheng JN; Chongqing Key Laboratory of Immunotherapy, Chongqing 400037, China.
  • Zuo X; Department of Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China.
  • Xu L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Fang H; Department of Bio-therapeutic, The First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Hu C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Peng L; Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.
  • Jin T; Chongqing Key Laboratory of Immunotherapy, Chongqing 400037, China.
  • Shi Z; Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.
  • Alexander PB; Chongqing Key Laboratory of Immunotherapy, Chongqing 400037, China.
  • Wang Y; Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.
  • Liu Y; Chongqing Key Laboratory of Immunotherapy, Chongqing 400037, China.
  • Han W; R&D Department, HRAIN Biotechnology Co. Ltd., Shanghai, China.
  • Zhu J; Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.
  • Wang P; Chongqing Key Laboratory of Immunotherapy, Chongqing 400037, China.
  • Li QJ; Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.
  • Zhu B; Chongqing Key Laboratory of Immunotherapy, Chongqing 400037, China.
Theranostics ; 11(10): 4699-4709, 2021.
Article em En | MEDLINE | ID: mdl-33754022
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Linfoma de Células B / Eosinófilos / Receptores de Antígenos Quiméricos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Theranostics Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Linfoma de Células B / Eosinófilos / Receptores de Antígenos Quiméricos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Theranostics Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China